Publication Details

Category Text Publication
Reference Category Journals
DOI 10.1016/j.jhepr.2025.101338
Licence creative commons licence
Title (Primary) Serum proteomics of adults with acute liver failure provides mechanistic insights and attractive prognostic biomarkers
Author Remih, K.; Hufnagel, F.-M.; Karl, A.S.; Durkalski-Mauldin, V.L.; Lee, W.M.; Karvellas, C.J.; Su, Z.; Rule, J.A.; Tomanová, P.; Krieg, L.; Karkossa, I.; Schubert, K.; von Bergen, M.; Tacke, F.; Luckhardt, S.; Ziegler, N.; Kannt, A.; Engel, B.; Taubert, R.; Fontana, R.J.; Strnad, P.; US Acute Liver Failure Study Group,
Source Titel JHEP Reports
Year 2025
Department MOLTOX
Volume 7
Issue 5
Page From art. 101338
Language englisch
Topic T9 Healthy Planet
Supplements Supplement 1
Supplement 2
Supplement 3
Supplement 4
Supplement 5
Keywords Acute liver injury; Proteomic profiling; Acetaminophen; ALF subtyping
Abstract Background & Aims
Acute liver failure (ALF) is defined as rapid onset coagulopathy and encephalopathy in patients without a prior history of liver disease. We performed untargeted and targeted serum proteomics to delineate processes occurring in adult patients with ALF and to identify potential biomarkers.
Methods
Sera of 319 adult patients with ALF (∼50% acetaminophen [APAP]-related cases) were randomly selected from admission samples of the multicenter USA Acute Liver Failure Study Group consortium and subdivided into discovery/validation cohorts. They were analyzed using untargeted proteomics with mass spectroscopy and a serum cytokine profiling and compared with 30 healthy controls. The primary clinical outcome was 21-day transplant-free survival. Single-cell RNAseq data mapped biomarkers to cells of origin; functional enrichment analysis provided mechanistic insights. Novel prognostic scores were compared with the model for end-stage liver disease and ALFSG prognostic index scores.
Results
In the discovery cohort, 117 proteins differed between patients with ALF and healthy controls. There were 167 proteins associated with APAP-related ALF, with the majority being hepatocyte-derived. Three hepatocellular proteins (ALDOB, CAT, and PIGR) robustly and reproducibly discriminated APAP from non-APAP cases (AUROCs ∼0.9). In the discovery cohort, 37 proteins were related to 21-day outcome. The key processes associated with survival were acute-phase response and hepatocyte nuclear factor 1α signaling. SERPINA1 and LRG1 were the best individual discriminators of 21-day transplant-free survival in both cohorts. Two models of blood-based proteomic biomarkers outperformed the model for end-stage liver disease and ALFSG prognostic index and were reproduced in the validation cohort (AUROCs 0.83-0.86) for 21-day transplant-free survival.
Conclusions
Proteomics and cytokine profiling identified new, reproducible biomarkers associated with APAP etiology and 21-day outcome. These biomarkers may improve prognostication and understanding of the etiopathogenesis of ALF but need to be independently validated.
Impact and implications
Acute liver failure (ALF) is a sudden, and severe condition associated with high fatality. More sensitive and specific prognostic scores are urgently needed to facilitate decision-making regarding liver transplantation in patients with ALF. Our proteomic analysis uncovered marked differences between acetaminophen and non-acetaminophen-related ALF. The identification of routinely measurable biomarkers that are associated with 21-day transplant-free survival and the derivation of novel prognostic scores may facilitate clinical management as well as decisions for/against liver transplantation. Further studies are needed to quantify less abundant proteins. Although we used two cohorts, our findings still need to be independently and prospectively validated.
Graphical abstract
Remih, K., Hufnagel, F.-M., Karl, A.S., Durkalski-Mauldin, V.L., Lee, W.M., Karvellas, C.J., Su, Z., Rule, J.A., Tomanová, P., Krieg, L., Karkossa, I., Schubert, K., von Bergen, M., Tacke, F., Luckhardt, S., Ziegler, N., Kannt, A., Engel, B., Taubert, R., Fontana, R.J., Strnad, P., US Acute Liver Failure Study Group, (2025):
Serum proteomics of adults with acute liver failure provides mechanistic insights and attractive prognostic biomarkers
JHEP Rep. 7 (5), art. 101338 10.1016/j.jhepr.2025.101338